Immunoprevention of cancer: Is the time ripe?

Guido Forni, Pier Luigi Lollini, Piero Musiani, Mario P. Colombo

Research output: Contribution to journalArticle

Abstract

Immunotherapy applied to patients with established tumors rarely leads to an objective response, whereas patients apparently free from disease after conventional treatment and at risk of recurrence are beginning to receive vaccination. New classes of patients or not-yet patients are those with a high genetic or environmental risk of developing cancer. They may draw benefit from a 'soft' treatment such as vaccination. This overview discusses the prospects of immune stimulation as a means of cancer prevention by inducing various forms of nonspecific or even specific immunity. Attainment of this goal provides the rationale and motivation for embarking on such a new and potentially rewarding enterprise.

Original languageEnglish
Pages (from-to)2571-2575
Number of pages5
JournalCancer Research
Volume60
Issue number10
Publication statusPublished - May 15 2000

Fingerprint

Neoplasms
Vaccination
Immunotherapy
Immunity
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Forni, G., Lollini, P. L., Musiani, P., & Colombo, M. P. (2000). Immunoprevention of cancer: Is the time ripe? Cancer Research, 60(10), 2571-2575.

Immunoprevention of cancer : Is the time ripe? / Forni, Guido; Lollini, Pier Luigi; Musiani, Piero; Colombo, Mario P.

In: Cancer Research, Vol. 60, No. 10, 15.05.2000, p. 2571-2575.

Research output: Contribution to journalArticle

Forni, G, Lollini, PL, Musiani, P & Colombo, MP 2000, 'Immunoprevention of cancer: Is the time ripe?', Cancer Research, vol. 60, no. 10, pp. 2571-2575.
Forni G, Lollini PL, Musiani P, Colombo MP. Immunoprevention of cancer: Is the time ripe? Cancer Research. 2000 May 15;60(10):2571-2575.
Forni, Guido ; Lollini, Pier Luigi ; Musiani, Piero ; Colombo, Mario P. / Immunoprevention of cancer : Is the time ripe?. In: Cancer Research. 2000 ; Vol. 60, No. 10. pp. 2571-2575.
@article{e846abbc24fb4d528d16a43db5584a5c,
title = "Immunoprevention of cancer: Is the time ripe?",
abstract = "Immunotherapy applied to patients with established tumors rarely leads to an objective response, whereas patients apparently free from disease after conventional treatment and at risk of recurrence are beginning to receive vaccination. New classes of patients or not-yet patients are those with a high genetic or environmental risk of developing cancer. They may draw benefit from a 'soft' treatment such as vaccination. This overview discusses the prospects of immune stimulation as a means of cancer prevention by inducing various forms of nonspecific or even specific immunity. Attainment of this goal provides the rationale and motivation for embarking on such a new and potentially rewarding enterprise.",
author = "Guido Forni and Lollini, {Pier Luigi} and Piero Musiani and Colombo, {Mario P.}",
year = "2000",
month = "5",
day = "15",
language = "English",
volume = "60",
pages = "2571--2575",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Immunoprevention of cancer

T2 - Is the time ripe?

AU - Forni, Guido

AU - Lollini, Pier Luigi

AU - Musiani, Piero

AU - Colombo, Mario P.

PY - 2000/5/15

Y1 - 2000/5/15

N2 - Immunotherapy applied to patients with established tumors rarely leads to an objective response, whereas patients apparently free from disease after conventional treatment and at risk of recurrence are beginning to receive vaccination. New classes of patients or not-yet patients are those with a high genetic or environmental risk of developing cancer. They may draw benefit from a 'soft' treatment such as vaccination. This overview discusses the prospects of immune stimulation as a means of cancer prevention by inducing various forms of nonspecific or even specific immunity. Attainment of this goal provides the rationale and motivation for embarking on such a new and potentially rewarding enterprise.

AB - Immunotherapy applied to patients with established tumors rarely leads to an objective response, whereas patients apparently free from disease after conventional treatment and at risk of recurrence are beginning to receive vaccination. New classes of patients or not-yet patients are those with a high genetic or environmental risk of developing cancer. They may draw benefit from a 'soft' treatment such as vaccination. This overview discusses the prospects of immune stimulation as a means of cancer prevention by inducing various forms of nonspecific or even specific immunity. Attainment of this goal provides the rationale and motivation for embarking on such a new and potentially rewarding enterprise.

UR - http://www.scopus.com/inward/record.url?scp=0034658656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034658656&partnerID=8YFLogxK

M3 - Article

C2 - 10825122

AN - SCOPUS:0034658656

VL - 60

SP - 2571

EP - 2575

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 10

ER -